Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Carmen Julia Calfa"'
Autor:
Pam K. Mangat, Suanna S. Bruinooge, Timothy L. Cannon, Sagun Shrestha, Nicole L. Butler, Julie Gottlieb Fisher, Andrew L. Rygiel, Sasha L. Warren, Damien Hansra, Carmen Julia Calfa, Richard L. Schilsky, Ajjai Alva, Eugene R Ahn, Susan Halabi, Maged F. Khalil, Shamika Ranasinghe, Pamela A. Crilley, Elizabeth Garrett-Mayer, Kaitlyn R. Antonelli, Derrick S. Haslem
Publikováno v:
Journal of Clinical Oncology. 39:2443-2451
PURPOSE The TAPUR Study is a phase II basket trial that aims to identify signals of antitumor activity of commercially available targeted agents in patients with advanced cancers harboring genomic alterations known to be drug targets. Results in a co
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b0d11946030606eb338dcd7d63df0e61
https://doi.org/10.1200/jco.20.02923
https://doi.org/10.1200/jco.20.02923
Autor:
Daniel Haggstrom, Pam K. Mangat, Susan Halabi, Ramya Thota, Anu G. Gaba, Kathryn B. Alguire, Elie G. Dib, Samiha Islam, Andrew L. Rygiel, Richard L. Schilsky, Elizabeth Garrett-Mayer, Eugene R Ahn, Kaitlyn R. Antonelli, Ashish Sangal, Pamela A. Crilley, Alissa S. Marr, Suanna S. Bruinooge, Carmen Julia Calfa, Timothy L. Cannon
Publikováno v:
JCO Precision Oncology. :757-766
PURPOSE The Targeted Agent and Profiling Utilization Registry (TAPUR) Study is a phase II pragmatic basket trial evaluating antitumor activity of commercially available targeted agents in patients with advanced cancer with genomic alterations known t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0ebd8ac56b9a652d3f8c3c3e769fbde8
https://doi.org/10.1200/po.20.00037
https://doi.org/10.1200/po.20.00037
Autor:
Timothy L. Cannon, Ramya Thota, Nicole D. Fleming, Susan Halabi, Ricardo H. Alvarez, Jared Addison Cotta, Pam K. Mangat, Carmen Julia Calfa, Pamela A. Crilley, Sasha L. Warren, Andrew L. Rygiel, Theodore Pollock, Dan Veljovich, Elizabeth Garrett-Mayer, Julian C. Schink, Tareq Al Baghdadi, Julie Gottlieb Fisher, David Tait, Richard L. Schilsky
Publikováno v:
Targeted Oncology. 15:733-741
The Targeted Agent and Profiling Utilization Registry (TAPUR) Study, a phase II basket study, evaluates anti-tumor activity of commercially available targeted agents in patients with advanced cancers harboring genomic alterations known as drug target
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bb8f26ee6714134e4308f039853e6ab7
https://doi.org/10.1007/s11523-020-00753-7
https://doi.org/10.1007/s11523-020-00753-7
Autor:
Funda Meric-Bernstam, Michael Rothe, Elizabeth Garrett-Mayer, Rodolfo Gutierrez, Eugene R Ahn, Timothy Lewis Cannon, Steven Francis Powell, John C. Krauss, Christopher M. Reynolds, Margaret von Mehren, Deepti Behl, Carmen Julia Calfa, Herbert Leon Duvivier, Henry G. Kaplan, Michael B. Livingston, Manish Sharma, Walter John Urba, Raegan O'Lone, Susan Halabi, Richard L. Schilsky
Publikováno v:
Journal of Clinical Oncology. 40:3008-3008
3008 Background: TAPUR is a phase II basket study evaluating anti-tumor activity of commercially available targeted agents in pts with advanced cancers with genomic alterations. Results in a cohort of pts with solid tumors with BRAF V600E/D/K/R mutat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e558c449c99dcbf7da40130d6c33eb00
https://doi.org/10.1200/jco.2022.40.16_suppl.3008
https://doi.org/10.1200/jco.2022.40.16_suppl.3008
Publikováno v:
Journal of Clinical Oncology. 40:e24048-e24048
e24048 Background: While treatment-related sexual health sequelae are documented using validated patient-reported outcome measures, the anatomic changes associated with cancer treatment are not well described, which may lead to an underestimation of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::90d361d7a6387a2e4c6412fb5a209cec
https://doi.org/10.1200/jco.2022.40.16_suppl.e24048
https://doi.org/10.1200/jco.2022.40.16_suppl.e24048
Autor:
Vijay S. Suhag, Forrest L. Thompson, Andrew L. Rygiel, Samiha Islam, Pam K. Mangat, Kathleen J. Yost, Alissa S. Marr, Ajjai Alva, Elizabeth Garrett-Mayer, Efrat Dotan, Olatunji B. Alese, Omid Hamid, Martin Clive Palmer, Eugene R Ahn, Eddy S. Yang, Carmen Julia Calfa, Susan Halabi, Sarah T. Anderson, Richard L. Schilsky
Publikováno v:
Journal of Clinical Oncology. 38:4637-4637
4637 Background: TAPUR is a phase II basket study evaluating anti-tumor activity of commercially available targeted agents in pts with advanced cancers with genomic alterations. Results in a cohort of pancreatic cancer pts with germline or somatic BR
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::018c6f360260a849482fec2d0a4db34e
https://doi.org/10.1200/jco.2020.38.15_suppl.4637
https://doi.org/10.1200/jco.2020.38.15_suppl.4637
Autor:
Eugene R Ahn, Anu G. Gaba, Suanna S. Bruinooge, Richard L. Schilsky, Ricardo H. Alvarez, Carmen Julia Calfa, Kaitlyn R. Antonelli, Elizabeth Garrett-Mayer, Samiha Islam, Elie G. Dib, Andrew L. Rygiel, Timothy L. Cannon, Alissa S. Marr, Ramya Thota, Kathryn B. Alguire, Susan Halabi, Daniel Haggstrom, Pamela A. Crilley, Ashish Sangal, Pam K. Mangat
Publikováno v:
Journal of Clinical Oncology. 37:9041-9041
9041 Background: TAPUR is a phase II basket study evaluating anti-tumor activity of commercially available targeted agents in pts with advanced cancers with genomic alterations. Results in a cohort of NSCLC pts with CDKN2A loss or mutation treated wi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::72cc24d37e72f0bfc29254af77a3cd0c
https://doi.org/10.1200/jco.2019.37.15_suppl.9041
https://doi.org/10.1200/jco.2019.37.15_suppl.9041
Autor:
Ajjai Shivaram Alva, Pam K. Mangat, Elizabeth Garrett-Mayer, Susan Halabi, Ricardo H. Alvarez, Carmen Julia Calfa, Maged F. Khalil, Eugene R Ahn, Timothy Lewis Cannon, Pamela A. Crilley, Julie Gottlieb Fisher, Derrick S. Haslem, Sagun Shrestha, Kaitlyn R. Antonelli, Nicole L. Butler, Sasha L. Warren, Andrew Lawrence Rygiel, Shamika Ranasinghe, Suanna S. Bruinooge, Richard L. Schilsky
Publikováno v:
Journal of Clinical Oncology. 37:1014-1014
1014 Background: TAPUR is a phase II basket study evaluating the anti-tumor activity of commercially available targeted agents in pts with advanced cancers with specific genomic alterations. P is an immune checkpoint inhibitor and HTMB is an emerging
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1067ff2c5027ebb830e86580fb6afe25
https://doi.org/10.1200/jco.2019.37.15_suppl.1014
https://doi.org/10.1200/jco.2019.37.15_suppl.1014
Publikováno v:
American Journal of Ophthalmology. 144:326-329
Purpose To present a case of T-cell chronic lymphocytic leukemia (T-CLL) manifesting as an intraocular lymphoma. Design Interventional case report. Methods We performed a vitreous biopsy in a 67-year-old woman who presented with blurred vision and vi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ab9e59439a4397bbf7f98ea2bdcd5a60
https://doi.org/10.1016/j.ajo.2007.03.031
https://doi.org/10.1016/j.ajo.2007.03.031
Autor:
Aruna Mani, Cynthia Frankel, Dina Bernie Dumercy, Alejandra T. Perez, Michel Velez, Carla Hawkins Locke, Irene Borrero, Carmen Julia Calfa, Candice Sareli, Evelio Velis, Aurelio Castrellon, Nicholas LeCroy
Publikováno v:
Journal of Clinical Oncology. 33:1048-1048
1048 Background: A preferred NAC regimen for HER2-negative BC is DDAC for 4 cycles followed by 12 weeks of T. RDI of 1 indicates that all intended doses are given at the scheduled interval. While l...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::65d33bf0ad65d6b0d3a5d97826ad2f29
https://doi.org/10.1200/jco.2015.33.15_suppl.1048
https://doi.org/10.1200/jco.2015.33.15_suppl.1048